Growth of Uveal Melanoma following Intravitreal Bevacizumab.

Journal: Ocular oncology and pathology
Published Date: Nov 12, 2016

Abstract

PURPOSE: Typically treatment of large melanomas (by Collaborative Ocular Melanoma Study criteria) is restricted to enucleation, due to size constraints for plaque brachytherapy. Because primary and metastatic uveal melanoma cells are inhibited by bevacizumab (an anti-vascular endothelial growth factor), this prospective study evaluated the impact of intravitreal bevacizumab on large uveal melanomas that were destined for enucleation. Size reduction by bevacizumab would potentially salvage these eyes by making them eligible for treatment with plaque brachytherapy.

Authors

  • Jasmine H Francis
    Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Jonathan Kim
    Department of Ophthalmology, University of Southern California, Los Angeles, CA, USA.
  • Amy Lin
    University of Illinois Hospital and Health Sciences System, Chicago, IL, USA.
  • Robert Folberg
    Oakland University William Beaumont School of Medicine, Rochester, MI, USA.
  • Saipriya Iyer
    Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • David H Abramson
    Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals